374 related articles for article (PubMed ID: 36419143)
1. Omadacycline for management of Mycobacterium abscessus infections: a review of its effectiveness, place in therapy, and considerations for use.
Rizzo AR; Moniri NH
BMC Infect Dis; 2022 Nov; 22(1):874. PubMed ID: 36419143
[TBL] [Abstract][Full Text] [Related]
2.
Zhang T; Du J; Dong L; Wang F; Zhao L; Jia J; Wang C; Cheng M; Yu X; Huang H
Microbiol Spectr; 2023 Feb; 11(1):e0323822. PubMed ID: 36475850
[TBL] [Abstract][Full Text] [Related]
3.
Brown-Elliott BA; Wallace RJ
Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33288634
[TBL] [Abstract][Full Text] [Related]
4. Potency of Omadacycline against Mycobacteroides abscessus Clinical Isolates
Nicklas DA; Maggioncalda EC; Story-Roller E; Eichelman B; Tabor C; Serio AW; Keepers TR; Chitra S; Lamichhane G
Antimicrob Agents Chemother; 2022 Jan; 66(1):e0170421. PubMed ID: 34662184
[TBL] [Abstract][Full Text] [Related]
5. Omadacycline in first-line combination therapy for pulmonary Mycobacterium abscessus infection: a case series.
Duah M; Beshay M
Int J Infect Dis; 2022 Sep; 122():953-956. PubMed ID: 35798234
[TBL] [Abstract][Full Text] [Related]
6. Mycobacteriological characteristics and treatment outcomes in extrapulmonary Mycobacterium abscessus complex infections.
Jeong SH; Kim SY; Huh HJ; Ki CS; Lee NY; Kang CI; Chung DR; Peck KR; Shin SJ; Koh WJ
Int J Infect Dis; 2017 Jul; 60():49-56. PubMed ID: 28522316
[TBL] [Abstract][Full Text] [Related]
7. Drug susceptibility profiles and factors associated with non-tuberculous mycobacteria species circulating among patients diagnosed with pulmonary tuberculosis in Tanzania.
Maya TG; Komba EV; Mensah GI; Mbelele PM; Mpagama SG; Mfinanga SG; Addo KK; Kazwala RR
PLoS One; 2022; 17(3):e0265358. PubMed ID: 35324922
[TBL] [Abstract][Full Text] [Related]
8.
Kaushik A; Ammerman NC; Martins O; Parrish NM; Nuermberger EL
Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30962331
[TBL] [Abstract][Full Text] [Related]
9. [A pharmacologic approach to treatment of Mycobacterium abscessus pulmonary disease].
Kassegne L; Veziris N; Fraisse P
Rev Mal Respir; 2024 Jan; 41(1):29-42. PubMed ID: 38016833
[TBL] [Abstract][Full Text] [Related]
10. Omadacycline therapy for Mycobacterium abscessus species infections.
Ingram PR; Jones EE; Allen B; Murray RJ; Keehner TJ; Whitmore TJ
Intern Med J; 2023 Dec; 53(12):2257-2263. PubMed ID: 36917124
[TBL] [Abstract][Full Text] [Related]
11. Sudapyridine (WX-081) antibacterial activity against
Zheng L; Wang H; Qi X; Zhang W; Wang B; Fu L; Chen X; Chen X; Lu Y
mSphere; 2024 Feb; 9(2):e0051823. PubMed ID: 38240581
[TBL] [Abstract][Full Text] [Related]
12. Genomic Analysis of Mycobacterium abscessus Complex Isolates from Patients with Pulmonary Infection in China.
Jin P; Dai J; Guo Y; Wang X; Lu J; Zhu Y; Yu F
Microbiol Spectr; 2022 Aug; 10(4):e0011822. PubMed ID: 35863029
[TBL] [Abstract][Full Text] [Related]
13.
Brown-Elliott BA; Wallace RJ
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0068922. PubMed ID: 35943269
[TBL] [Abstract][Full Text] [Related]
14. Molecular Identification of Strains within the
Kania K; Wόjcik K; Czekajewska J; Grzesiak M; Klesiewicz K
Pol J Microbiol; 2023 Dec; 72(4):491-506. PubMed ID: 38103008
[TBL] [Abstract][Full Text] [Related]
15. Disseminated nontuberculous mycobacteria infection in an immunocompetent host: A case report.
Shin HS; Yang B; Kim SR; Kim HS; Shin KS; Shin YM
Medicine (Baltimore); 2023 Jan; 102(1):e32416. PubMed ID: 36607850
[TBL] [Abstract][Full Text] [Related]
16.
Kim DH; Jhun BW; Moon SM; Kim SY; Jeon K; Kwon OJ; Huh HJ; Lee NY; Shin SJ; Daley CL; Koh WJ
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182533
[TBL] [Abstract][Full Text] [Related]
17. In Vitro Antimicrobial Susceptibility of Nontuberculous Mycobacteria in Iran.
Heidarieh P; Mirsaeidi M; Hashemzadeh M; Feizabadi MM; Bostanabad SZ; Nobar MG; Hashemi Shahraki A
Microb Drug Resist; 2016 Mar; 22(2):172-8. PubMed ID: 26468990
[TBL] [Abstract][Full Text] [Related]
18. Omadacycline drug susceptibility testing for non-tuberculous mycobacteria using oxyrase to overcome challenges with drug degradation.
Boorgula GD; Gumbo T; Singh S; McShane PJ; Philley JV; Srivastava S
Tuberculosis (Edinb); 2024 Jul; 147():102519. PubMed ID: 38754247
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology of Mycobacterium abscessus.
Cristancho-Rojas C; Varley CD; Lara SC; Kherabi Y; Henkle E; Winthrop KL
Clin Microbiol Infect; 2024 Jun; 30(6):712-717. PubMed ID: 37778416
[TBL] [Abstract][Full Text] [Related]
20.
Fujiwara K; Aono A; Asami T; Morimoto K; Kamada K; Morishige Y; Igarashi Y; Chikamatsu K; Murase Y; Yamada H; Takaki A; Mitarai S
Antimicrob Agents Chemother; 2023 Jun; 67(6):e0157922. PubMed ID: 37154742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
